FDA Aligns on Labeling for NRx’s Preservative-Free Ketamine

Event summary

  • FDA’s Office of Generic Drugs preliminarily aligned on labeling for NRx’s preservative-free ketamine, pending final supervisory review.
  • NRx expects to submit the final label this month, with anticipated approval under GDUFA in Summer 2026.
  • The product aims to address ketamine supply shortages, aligning with FDA’s focus on re-shoring critical drug manufacturing.
  • NRx also plans to file a New Drug Application under Fast Track Designation for intravenous ketamine to treat severe depression with suicidal ideation.

The big picture

NRx’s preservative-free ketamine aligns with broader FDA priorities around domestic drug manufacturing and supply chain resilience. The strategic focus on re-shoring critical pharmaceutical production positions NRx to capitalize on regulatory and market tailwinds, particularly as ketamine demand outstrips supply. Success here could reinforce NRx’s role in the CNS therapeutics space, though execution risks remain.

What we're watching

Regulatory Execution
Whether NRx can secure final FDA approval by Summer 2026, avoiding delays in labeling or supervisory review.
Market Impact
How NRx’s preservative-free ketamine will compete in a market with existing supply constraints and potential new entrants.
Strategic Expansion
The pace at which NRx advances its Fast Track Designation application for treating severe depression with suicidal ideation.